Sarcopenia - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2017, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes medications and hormone replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia - Overview
Sarcopenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia - Companies Involved in Therapeutics Development
Amgen Inc
Biophytis SAS
GlaxoSmithKline Plc
MYOS RENS Technology Inc
Neurotune AG
Novartis AG
PsiOxus Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sarcopenia - Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEP-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia
Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
Sep 22, 2016: BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase
Aug 26, 2016: BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sarcopenia
Jul 25, 2016: BIOPHYTIS Receives Belgian Regulatory Authorization to Start Sarconeos Pharmacokinetics Study in Elderly Healthy Volunteers (SARA-PK)
Apr 12, 2016: BIOPHYTIS to Present Key Research Findings on Company Lead Compound at Upcoming Scientific Conferences
Mar 11, 2016: BIOPHYTIS Receives positive Scientific Advice on SARCOB BIO101 Clinical Development Plan from Belgian Regulatory Authority
Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th
Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob
Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Sarcopenia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Sarcopenia - Pipeline by Amgen Inc, H1 2017
Sarcopenia - Pipeline by Biophytis SAS, H1 2017
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H1 2017
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H1 2017
Sarcopenia - Pipeline by Neurotune AG, H1 2017
Sarcopenia - Pipeline by Novartis AG, H1 2017
Sarcopenia - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Sarcopenia - Dormant Projects, H1 2017
Sarcopenia - Discontinued Products, H1 2017